NEWM&A

Gilead (GILD) acquires Tubulis for $5 billion investment

Published on 4/7/2026

#GILD#M&A#biotech#oncology
Gilead (GILD) acquires Tubulis for $5 billion investment

AI Summary

Gilead Sciences (GILD) has announced the acquisition of Tubulis, a company specializing in antibody-drug conjugates, for a sum of $5 billion. This acquisition reflects Gilead's strategic investment to enhance its pipeline in cancer therapies. The increasing focus on advanced treatment options in oncology could impact Gilead's market position and future earnings. The transaction is expected to strengthen Gilead's capabilities in developing targeted therapies.

Source: Read original article (opens in new tab)

Related News

Universal Music Group (UMG) Soars 13% on $64 Billion Acquisition Proposal
M&A

Universal Music Group (UMG) Soars 13% on $64 Billion Acquisition Proposal

Apr 7

ReposiTrak (RPTK) Adds 18 New Produce Suppliers to Network
M&A

ReposiTrak (RPTK) Adds 18 New Produce Suppliers to Network

Apr 7

Boxlight (BOXL) converts $556,200 debt into shares under agreement
M&A

Boxlight (BOXL) converts $556,200 debt into shares under agreement

Apr 7

CABLE ONE DEF 14A Filing Details for April 7, 2023
M&A

CABLE ONE DEF 14A Filing Details for April 7, 2023

Apr 7